keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophagic junction cancer

keyword
https://www.readbyqxmd.com/read/29776635/molecular-diagnostics-in-esophageal-and-gastric-neoplasms-2018-update
#1
REVIEW
Muhammad Zulfiqar, Martin H Bluth, Amarpreet Bhalla
Esophageal cancer (EC) is rapidly increasing in incidence in the United States. Genetic changes associated with the development of EC involve the p16, p53, and APC genes. Human epidermal growth factor 2 (HER-2) overexpression is seen in gastroesophageal junction carcinoma and a subset gastric carcinoma (GC). Interestingly, up to 50% cases of GC are related to Helicobacter pylori infection and up to 16% are related to EBV infection. Microsatellite instability is observed in up to 39% of GC and cell free nucleic acid analysis provides additional opportunities for diagnosis and prognosis of disease...
June 2018: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29768350/docetaxel-oxaliplatin-5fu-and-trastuzumab-as-first-line-therapy-in-patients-with-human-epidermal-receptor-2-positive-advanced-gastric-or-gastroesophageal-junction-cancer-preliminary-results-of-a-phase-ii-study
#2
Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29765526/esophageal-cancer-cells-resistant-to-t-dm1-display-alterations-in-cell-adhesion-and-the-prostaglandin-pathway
#3
Juliette Sauveur, Eva-Laure Matera, Kamel Chettab, Philippe Valet, Jerome Guitton, Ariel Savina, Charles Dumontet
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that specifically targets HER2 thanks to its antibody component trastuzumab. In spite of responses to this novel agent, acquired resistance to treatment remains a major obstacle. Prolonged in vitro exposure of the gastroesophageal junction cancer cell line OE-19 to T-DM1, in the absence or presence of ciclosporin A resulted in the selection of two resistant cell lines to T-DM1. T-DM1-resistant cells presented an increased expression of adhesion genes, altered spreading and higher sensitivity to anoikis than parental cells...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29765235/fatal-hemoptysis-in-patients-with-advanced-esophageal-cancer-treated-with-apatinib
#4
Wei Wang, Lin Zhang, Yan Xie, Tianchang Zhen, Gongzhang Su, Qi Zang
Targeted therapy is commonly used for treating advanced malignant tumors. Compared with cytotoxic drugs, targeted drugs have the characteristics of good curative results, less adverse effects, and convenient oral administration. Hence, they are especially suitable for patients with cancer who are not able to tolerate chemotherapy. Anti-angiogenic therapy can achieve the objective by inhibiting the formation of new blood vessels in tumors. Apatinib is a novel tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29730461/evolution-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-gastric-cancers-current-status-and-future-perspectives
#5
REVIEW
Julien Taieb, Markus Moehler, Narikazu Boku, Jaffer A Ajani, Eduardo Yañez Ruiz, Min-Hee Ryu, Silke Guenther, Vikram Chand, Yung-Jue Bang
BACKGROUND: Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. METHODS: Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials...
April 22, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29725881/a-multicentre-open-label-phase-ii-study-of-irinotecan-capecitabine-xeloda%C3%A2-and-oxaliplatin-ixo-as-first-line-treatment-in-patients-with-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma
#6
Arthur Lui, Karen Mulder, Christine Brezden-Masley, Michael Vickers, Jose Monzon, Hagen Kennecke, Rakesh Goel, Larissa Vos, Sunita Ghosh, Horia Marginean, Anthony Fields, Jean Maroun, Jennifer Spratlin
Purpose Chemotherapy remains the primary treatment for metastatic gastric/GEJ cancer but optimal agents and schedule remain controversial. This study examined the safety and efficacy of first-line Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO). Patients and Methods Eligible patients with HER2-unamplified/unknown, metastatic gastric/GEJ adenocarcinoma were treated with 21-day cycle IXO at dose level 1 (DL1: Day 1 O-100 mg/m2 & I-160 mg/m2 IV, Day 2-15 X-1900 mg/m2 /day PO divided doses) or modified IXO (mIXO): Day 1 O-85 mg/m2 & I-120 mg/m2 IV, Day 2-15 X-1425 mg/m2 /day PO divided doses)...
May 4, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29707301/lymph-node-metastases-near-the-celiac-trunk-should-be-considered-separately-from-other-nodal-metastases-in-patients-with-cancer-of-the-esophagus-or-gastroesophageal-junction-after-neoadjuvant-treatment-and-surgery
#7
Sjoerd M Lagarde, Martinus C J Anderegg, Suzanne S Gisbertz, Sybren L Meijer, Maarten C C M Hulshof, Jacques J G H M Bergman, Hanneke W M van Laarhoven, Mark I van Berge Henegouwen
Background: The aim of the present study is to identify the incidence and prognostic significance of lymph node metastases near the celiac trunk in patients who underwent neoadjuvant chemo(radio)therapy followed by esophagectomy. Methods: Between March 1994 and September 2013 a total of 462 consecutive patients with cancer of the esophagus or gastroesophageal junction (GEJ) who underwent potentially curative esophageal resection after neoadjuvant chemotherapy (N=88; 19...
March 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29703766/immuno-oncology-biomarkers-for-gastric-and-gastroesophageal-junction-adenocarcinoma-why-pd-l1-testing-may-not-be-enough
#8
Benjamin A Weinberg, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, Mohamed E Salem, John L Marshall
PURPOSE: The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD-L1) protein by companion diagnostic testing. However, some patients with PD-L1-negative tumors also benefit from pembrolizumab. High microsatellite instability (MSI) and tumor mutational load (TML) are positive predictive biomarkers for immune checkpoint inhibition (ICI) in other tumors...
April 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29681813/hyperprogressive-disease-in-the-irradiation-field-after-a-single-dose-of-nivolumab-for-gastric-cancer-a-case-report
#9
Takatsugu Ogata, Hironaga Satake, Misato Ogata, Yukimasa Hatachi, Hisateru Yasui
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiotherapy only to experience rapid progression within the irradiation field after the first immunotherapy session. A 66-year-old man with dysphagia visited our hospital and was diagnosed with stage IV gastroesophageal cancer (human epidermal growth factor receptor-2 score = 0)...
January 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29674442/first-report-of-dramatic-tumor-responses-with-ramucirumab-and-paclitaxel-after-progression-on-pembrolizumab-in-two-cases-of-metastatic-gastroesophageal-adenocarcinoma
#10
Sakti Chakrabarti, Haidong Dong, Harshita R Paripati, Helen J Ross, Harry H Yoon
Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29670922/clinicopathological-features-and-increased-expression-of-toll-like-receptor-4-of-gastric-cardia-cancer-in-a-high-risk-chinese-population
#11
Guangcan Chen, Muming Xu, Jingyao Chen, Liangli Hong, Wenting Lin, Shukun Zhao, Guohong Zhang, Guo Dan, Shuhui Liu
The incidence of gastric cardia cancer (GCC) is high in China. However, the clinicopathological characteristics and the carcinogenesis of GCC are unclear. Toll-like receptor 4 (TLR4) is an important innate immunity receptor and has a role in non-GCC (NGCC). We compared the clinicopathological characteristics of GCC patients from a high-risk area in China to esophageal cancer (EC) patients. Immunohistochemistry for TLR4 was performed in 201 histological samples of normal gastric cardia mucosa ( n = 11), gastric cardia inflammation ( n = 87), and GCC ( n = 103)...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29668913/defining-pneumonia-after-esophagectomy-for-cancer-validation-of-the-uniform-pneumonia-score-in-a-high-volume-center-in-north-america
#12
M F J Seesing, A Wirsching, P S N van Rossum, T J Weijs, J P Ruurda, R van Hillegersberg, D E Low
Surgery is a central component of multimodality therapy for esophageal and gastroesophageal junction cancer. Pneumonia is a common sequela of esophagectomy, leading to an increase in intensive care unit stay, hospital stay, readmission rates, and postoperative mortality. Developing strategies to reduce pneumonia after esophagectomy is hampered by the absence of a standardized methodology for defining pneumonia. This study aims to validate the Uniform Pneumonia Score (UPS) in a high volume center in the USA...
April 14, 2018: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/29663302/multivisceral-resection-for-locally-advanced-gastric-and-gastroesophageal-junction-cancers-11-year-experience-at-a-high-volume-north-american-center
#13
J C Molina, A Al-Hinai, A Gosseling-Tardif, P Bouchard, J Spicer, D Mulder, C L Mueller, L E Ferri
INTRODUCTION: The oncologic benefit of multivisceral en bloc resections for T4 gastroesophageal tumors has been questioned, given the increased morbidity associated. We thus sought to investigate the surgical and oncologic outcomes of curative-intent en bloc multivisceral resections for T4 gastroesophageal carcinomas. METHODS: Between 2005 and 2016, 35 of the 525 patients who had gastric or EGJ carcinomas underwent curative-intent multivisceral resections for direct invasion or adhesion to adjacent organs...
April 16, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29611027/prevalence-and-prognostic-significance-of-extramural-venous-invasion-in-patients-with-locally-advanced-esophageal-cancer
#14
Zohra Faiz, Lotte J W Huijgen, H J Alqethami, J G M Burgerhof, Gursah Kats-Ugurlu, John T M Plukker
BACKGROUND: Extramural venous invasion (EMVI) is a known adverse prognostic factor in patients with colorectal carcinoma. The prevalence and significance of EMVI in esophageal cancer (EC) patients is still unclear. METHODS: From a prospectively maintained database, we retrospectively reviewed the resection specimens of patients with pathologic locally advanced (pT3/T4/N0-3) EC who were treated with curative intent between 2000 and 2015. Patients with previous malignancies and gastroesophageal junction (type II/III) tumors were excluded...
April 2, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29601052/the-role-of-neoadjuvant-chemoradiotherapy-in-multimodality-treatment-of-esophageal-or-gastroesophageal-junction-cancer
#15
COMMENT
Fredrik Klevebro, Magnus Nilsson
No abstract text is available yet for this article.
January 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29594228/vmat-radiation-induced-nausea-and-vomiting-in-adjuvant-breast-cancer-radiotherapy-the-incidental-effect-of-low-dose-bath-exposure
#16
G Lazzari, A Terlizzi, M G Leo, G Silvano
Background and purpose: To investigate the hypothesis on low-dose bath exposure related to radiation-induced nausea and vomiting (RINV) in adjuvant breast volumetric modulated arch therapy (VMAT). Methods and materials: A total of 106 consecutive breast cancer patients (pts) treated with adjuvant radiotherapy (RT) with VMAT from January 2013 to May 2016 were evaluated retrospectively. For each pt, a planning CT was reimported and the coeliac plexus and gastroesophageal junction with gastric mouth (GEJCPs) were contoured as a new organ at risk (OAR) in the upper abdominal area...
December 2017: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29552209/gastric-cancer-with-brain-metastasis-and-the-role-of-human-epidermal-growth-factor-2-status
#17
Luigi Cavanna, Pietro Seghini, Camilla Di Nunzio, Elena Orlandi, Emanuele Michieletti, Elisa Maria Stroppa, Patrizia Mordenti, Chiara Citterio, Stefano Vecchia, Adriano Zangrandi
Central nervous system (CNS) metastases from cancers of the gastrointestinal tract (GIT) are rare, and occur in 0.16-0.69% of patients with gastric or gastro-esophageal (GE) junction cancer. Overexpression of the human epidermal growth factor 2 (HER-2) is associated with poor prognosis in the absence of HER-2-targeted therapy, and with an increased incidence of CNS metastases in patients with breast cancer. The role of HER-2 overexpression in CNS metastases is not well known in gastric adenocarcinoma. The purpose of the present retrospective study was to assess the incidence of CNS metastases and to evaluate the associations between the CNS and HER-2 status in a series of consecutive patients with gastric or GE junction cancer...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29544445/long-term-trastuzumab-herceptin%C3%A2-treatment-in-a-continuation-study-of-patients-with-her2-positive-breast-cancer-or-her2-positive-gastric-cancer
#18
Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing, Yung-Jue Bang
BACKGROUND: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively)...
March 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29543932/safety-and-efficacy-of-pembrolizumab-monotherapy-in-patients-with-previously-treated-advanced-gastric-and-gastroesophageal-junction-cancer-phase-2-clinical-keynote-059-trial
#19
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A Wainberg, Daniel V Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H Ko, Geoffrey Ku, Philip Philip, Peter C Enzinger, Yung-Jue Bang, Diane Levitan, Jiangdian Wang, Minori Rosales, Rita P Dalal, Harry H Yoon
Importance: Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective: To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. Design, Setting, and Participants: In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016...
March 15, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29508095/ramucirumab-for-the-treatment-of-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma-following-disease-progression-on-first-line-platinum-or-fluoropyrimidine-containing-combination-therapy-in-japanese-patients-a-phase-2-open-label-study
#20
Kensei Yamaguchi, Kazumasa Fujitani, Fumio Nagashima, Yasushi Omuro, Nozomu Machida, Tomohiro Nishina, Toshiko Koue, Mika Tsujimoto, Kaijiro Maeda, Taroh Satoh
BACKGROUND: Ramucirumab, a monoclonal antibody vascular endothelial growth factor receptor-2 antagonist, given as monotherapy improved survival in a global phase 3 study (REGARD) of patients with gastric cancer. However, REGARD did not include Japanese patients. This study evaluated the efficacy and safety of ramucirumab monotherapy in Japanese patients with advanced gastric cancer. METHODS: This multicenter, open-label, nonrandomized phase 2 study (Clinicaltrials...
March 5, 2018: Gastric Cancer
keyword
keyword
110187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"